Manchester Capital Management’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $22.1K | Buy |
113
+8
| +8% | +$1.55K | ﹤0.01% | 657 |
|
|
2025
Q4 | $18.2K | Sell |
105
-7
| -6% | -$1.27K | ﹤0.01% | 678 |
|
|
2025
Q3 | $21.3K | Buy |
112
+21
| +23% | +$3.73K | ﹤0.01% | 735 |
|
|
2025
Q2 | $16.3K | Hold |
91
| – | – | ﹤0.01% | 759 |
|
|
2025
Q1 | $15.4K | Sell |
91
-17
| -16% | -$2.79K | ﹤0.01% | 763 |
|
|
2024
Q4 | $16.3K | Buy |
108
+21
| +24% | +$3.27K | ﹤0.01% | 740 |
|
|
2024
Q3 | $13.5K | Buy |
87
+18
| +26% | +$2.69K | ﹤0.01% | 753 |
|
|
2024
Q2 | $9.45K | Buy |
69
+12
| +21% | +$1.64K | ﹤0.01% | 766 |
|
|
2024
Q1 | $7.59K | Buy |
57
+22
| +63% | +$2.85K | ﹤0.01% | 671 |
|
|
2023
Q4 | $4.83K | Sell |
35
-8
| -19% | -$1.05K | ﹤0.01% | 707 |
|
|
2023
Q3 | $5.24K | Buy |
43
+17
| +65% | +$2.27K | ﹤0.01% | 644 |
|
|
2023
Q2 | $3.65K | Buy |
26
+15
| +136% | +$2.07K | ﹤0.01% | 658 |
|
|
2023
Q1 | $1.56K | Buy |
11
+8
| +267% | +$1.15K | ﹤0.01% | 841 |
|
|
2022
Q4 | $469 | Buy |
+3
| New | +$431 | ﹤0.01% | 918 |
|
|
2022
Q2 | – | Sell |
-3
| Closed | – | – | 1006 |
|
|
2022
Q1 | $0 | Sell |
3
-4
| -57% | -$558 | ﹤0.01% | 1050 |
|
|
2021
Q4 | $1K | Sell |
7
-4
| -36% | -$609 | ﹤0.01% | 923 |
|
|
2021
Q3 | $2K | Sell |
11
-89
| -89% | -$13K | ﹤0.01% | 849 |
|
|
2021
Q2 | $13K | Hold |
100
| – | – | ﹤0.01% | 478 |
|
|
2021
Q1 | $13K | Buy |
+100
| New | +$12.3K | ﹤0.01% | 462 |
|
|
2020
Q3 | – | Sell |
-250
| Closed | -$28K | – | 581 |
|
|
2020
Q2 | $28K | Hold |
250
| – | – | ﹤0.01% | 408 |
|
|
2020
Q1 | $20K | Hold |
250
| – | – | ﹤0.01% | 426 |
|
|
2019
Q4 | $27K | Hold |
250
| – | – | ﹤0.01% | 417 |
|
|
2019
Q3 | $27K | Hold |
250
| – | – | ﹤0.01% | 413 |
|
|
2019
Q2 | $25K | Hold |
250
| – | – | ﹤0.01% | 435 |
|
|
2019
Q1 | $22K | Hold |
250
| – | – | ﹤0.01% | 503 |
|
|
2018
Q4 | $27K | Hold |
250
| – | – | ﹤0.01% | 402 |
|
|
2018
Q3 | $27K | Hold |
250
| – | – | ﹤0.01% | 409 |
|
|
2018
Q2 | $27K | Sell |
250
-67
| -21% | -$6.98K | ﹤0.01% | 414 |
|
|
2018
Q1 | $32K | Buy |
317
+67
| +27% | +$6.86K | 0.01% | 395 |
|
|
2017
Q4 | $25K | Hold |
250
| – | – | ﹤0.01% | 401 |
|
|
2017
Q3 | $23K | Hold |
250
| – | – | ﹤0.01% | 399 |
|
|
2017
Q2 | $28K | Hold |
250
| – | – | ﹤0.01% | 389 |
|
|
2017
Q1 | $25K | Hold |
250
| – | – | ﹤0.01% | 410 |
|
|
2016
Q4 | $23K | Hold |
250
| – | – | ﹤0.01% | 409 |
|
|
2016
Q3 | $21K | Hold |
250
| – | – | ﹤0.01% | 421 |
|
|
2016
Q2 | $20K | Hold |
250
| – | – | ﹤0.01% | 439 |
|
|
2016
Q1 | $18K | Hold |
250
| – | – | ﹤0.01% | 503 |
|
|
2015
Q4 | $18K | Hold |
250
| – | – | ﹤0.01% | 576 |
|
|
2015
Q3 | $15K | Hold |
250
| – | – | ﹤0.01% | 564 |
|
|
2015
Q2 | $18K | Hold |
250
| – | – | ﹤0.01% | 486 |
|
|
2015
Q1 | $19K | Sell |
250
-26
| -9% | -$1.86K | ﹤0.01% | 467 |
|
|
2014
Q4 | $19K | Hold |
276
| – | – | ﹤0.01% | 890 |
|
|
2014
Q3 | $17K | Hold |
276
| – | – | ﹤0.01% | 900 |
|
|
2014
Q2 | $16K | Sell |
276
-129
| -32% | -$7.55K | ﹤0.01% | 890 |
|
|
2014
Q1 | $23K | Buy |
405
+38
| +10% | +$2.04K | ﹤0.01% | 746 |
|
|
2013
Q4 | $20K | Hold |
367
| – | – | ﹤0.01% | 720 |
|
|
2013
Q3 | $23K | Hold |
367
| – | – | ﹤0.01% | 728 |
|
|
2013
Q2 | $22K | Buy |
+367
| New | +$21.9K | ﹤0.01% | 729 |
|
Other funds holding DGX
VCM
VPM
EIG
Manchester Capital Management's DGX Position: Q1 2026 in Review
Manchester Capital Management increased its Quest Diagnostics (DGX) stake by 7.6% in Q1 2026, buying an estimated $1.55K and bringing the position to 113 shares worth $22.1K. The position accounts for ﹤0.01% of the portfolio, ranked #657.
Manchester Capital Management first reported a position in DGX in Q2 2013 and has held it in 48 quarters since. The position peaked at $32K in Q1 2018. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.
- Manchester Capital Management held 113 shares of Quest Diagnostics worth $22.1K as of Q1 2026.
- Manchester Capital Management bought 8 Quest Diagnostics shares in Q1 2026, an estimated $1.55K.
- Quest Diagnostics made up ﹤0.01% of Manchester Capital Management's portfolio in Q1 2026, its #657 holding.
- Manchester Capital Management first reported a position in Quest Diagnostics in Q2 2013 and has held it in 48 quarters since.
- Manchester Capital Management's Quest Diagnostics position peaked at $32K in Q1 2018.
- 1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.
Based on Manchester Capital Management's 13F filing for Q1 2026, filed 11 May 2026.